# Suzhou Suncadia Biopharmaceuticals Co. trials: 104 (2026)

ClinicalTrials.gov lists 104 trials with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor, 62 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Suzhou Suncadia Biopharmaceuticals Co., Ltd.: 104 rows for $5.20, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 104
- Recruiting or not yet: 62
- Read on: November 19, 2026

## Trials

The 25 newest of 104, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 26, 2026 | NCT07896005 | A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896005) |
| October 26, 2026 | NCT07895992 | SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non-squamous Non-small Cell Lung Cancer | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895992) |
| October 7, 2026 | NCT07863167 | An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Non-small Cell Lung Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863167) |
| September 21, 2026 | NCT07830199 | A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Solid Tumor | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830199) |
| August 21, 2026 | NCT07779538 | Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Ovarian Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779538) |
| August 7, 2026 | NCT07751341 | A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751341) |
| July 30, 2026 | NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Prostate Cancer | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735377) |
| July 27, 2026 | NCT07726992 | A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Papillary-Only Non-muscle-invasive Bladder Cancer | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726992) |
| July 15, 2026 | NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Resectable Non-small Cell Lung Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704645) |
| July 9, 2026 | NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691762) |
| July 2, 2026 | NCT07682272 | A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682272) |
| July 1, 2026 | NCT07679360 | A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Triple Negative Breast Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679360) |
| June 30, 2026 | NCT07676903 | A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Solid Tumor | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676903) |
| June 30, 2026 | NCT07676162 | A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Advanced Colorectal Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676162) |
| June 22, 2026 | NCT07661537 | A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | B-cell Non-Hodgkin Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661537) |
| June 17, 2026 | NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652281) |
| March 24, 2026 | NCT07489716 | A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489716) |
| March 17, 2026 | NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Advanced Unresectable Hepatocellular Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478302) |
| March 6, 2026 | NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2/3 | Recruiting | Locally Advanced Resectable Rectal Cancer | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454720) |
| March 5, 2026 | NCT07450976 | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Biliary Tract Cancer | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450976) |
| February 20, 2026 | NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | NMIBC | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424287) |
| February 18, 2026 | NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Recurrent Cervical Cancer, Metastatic Cervical Cancer | 398 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418749) |
| February 17, 2026 | NCT07414602 | A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Dermatitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414602) |
| February 6, 2026 | NCT07393542 | A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Locally Advanced or Metastatic Urothelial Carcinoma | 453 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393542) |
| December 23, 2025 | NCT07298772 | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298772) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 28 |
| Phase 1/2 | 20 |
| Phase 2 | 22 |
| Phase 2/3 | 6 |
| Phase 3 | 27 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 53 |
| Unknown | 17 |
| Active not recruiting | 11 |
| Not yet recruiting | 9 |
| Completed | 8 |
| Terminated | 5 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Ovarian Neoplasms | 4 |
| Triple Negative Breast Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Biliary Tract Neoplasms | 3 |
| Multiple Myeloma | 2 |
| Colorectal Neoplasms | 2 |
| Recurrence | 2 |
| Arthritis, Psoriatic | 2 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Lupus Nephritis | 1 |
| Dermatitis | 1 |
| Carcinoma, Hepatocellular | 1 |
| Lymphoma, B-Cell | 1 |
| Carcinoma, Transitional Cell | 1 |
| Spondylitis, Ankylosing | 1 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Osteoporosis | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Stomach Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
